Compare RWT & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RWT | CDNA |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | United States |
| Employees | 351 | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.5M | 1.1B |
| IPO Year | N/A | 2007 |
| Metric | RWT | CDNA |
|---|---|---|
| Price | $5.26 | $20.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $6.82 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.2M | 742.5K |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 12.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $26.59 | $16.01 |
| Revenue Next Year | $22.21 | $11.31 |
| P/E Ratio | ★ N/A | $428.60 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $5.00 | $10.96 |
| 52 Week High | $6.97 | $23.24 |
| Indicator | RWT | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 31.02 | 52.61 |
| Support Level | $5.04 | $16.63 |
| Resistance Level | $5.39 | $21.20 |
| Average True Range (ATR) | 0.14 | 1.41 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 4.00 | 51.65 |
Redwood Trust Inc is a specialty finance company focused on several distinct areas of housing credit. The company delivers customized housing credit investments to a diverse mix of investors through securitization platforms, whole-loan distribution activities, and its publicly traded securities. The company has four reportable segments: Sequoia Mortgage Banking, CoreVest Mortgage Banking, Redwood Investments, and Legacy Investments. Maximum revenue is generated from the Sequoia Mortgage Banking segment, comprising a mortgage loan conduit that acquires residential consumer loans from third-party originators for subsequent sale to whole loan buyers, securitization through its SEMT private-label securitization program, or transfer into its Redwood Investments portfolio.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.